Kenostart

Main information

  • Trade name:
  • Kenostart
  • Pharmaceutical form:
  • Teat dip solution
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Kenostart
    Ireland
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • DISINFECTANTS
  • Therapeutic area:
  • Cattle

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0229/001
  • Authorization date:
  • 03-09-2011
  • EU code:
  • UK/V/0229/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Revised:May2011

AN:00478/2010

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Kenostart3mg/gTeatdipSolutionforcattle(Dairy)

France:Kenodip30003mg/gsolutionpourletrempagedestrayonschezla

vachelaitière

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Qualitativecomposition:

AvailableIodine,

Forafulllistofexcipientsseesection6.1 Quantitativecomposition:

3mg/g

3. PHARMACEUTICALFORM

TeatDipSolution

Viscousdarkbrownsolution

4. CLINICALPARTICULARS

4.1 Targetspecies

Cattle(dairy)

4.2 Indicationsforuse,specifyingthetargetspecies

Teatdisinfectionaspartofapreventionstrategyformastitisincattle

4.3 Contraindications

Donotuseincaseofknownhypersensitivitytoiodineoranyotherexcipients

4.4 Specialwarningsforeachtargetspecies

None

4.5 Specialprecautionsforuse

i.Specialprecautionsforuseinanimals

Forexternaluseonly

Useforthetreatmentofteatwithcutaneouslesionsmaydelay

wound-healingprocess.Itisrecommendedtodiscontinuethe

treatmentuntillesionsarehealed.

ii.Specialprecautionsforthepersonadministeringtheveterinarymedicinal

producttoanimals

Revised:May2011

AN:00478/2010

Avoidcontactwitheyes.Ifsplashedintheeye,rinsewithclean

runningwaterandseekmedicaladvice.

Incaseofingestion,drinklargequantitiesofwaterandseek

medicalattentionimmediately.

Keepawayfromfoodandanimalfeed.

Washhandsafteruse.

Iodinehasanallergicalpotential.Personswithknowniodine

hypersentitivitymustnothandletheproduct.

4.6 Adversereactions(frequencyandseriousness)

NoneKnown

4.7 Useduringpregnancy,lactationorlay

Canbeusedinlactatingandpregnantcattle

4.8 Interactionwithothermedicinalproductsandotherformsofinteraction

Noneknown.Donotmixwithotherchemicals

4.9 Amount(s)tobeadministeredandadministrationroute

Theproductissuppliedreadytouseasateatdip.Thedipcupshouldholdat

least5mlofdip.Dipeachteatimmediatelyaftermilking.Ensurethattheteatis

completelycoveredtothreequartersofitslength.TheDipcupshouldbe

replenishedasnecessary.Thedipcupshouldbeemptiedaftertreatmentand

washedbeforereuse.Theproductismeanttobeusedasapost-milkingteatdip

uptotwotimesperday.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Notapplicable,productisfortopicalapplication,significantabsorptiondoesnot

occur.

4.11Withdrawalperiod(s)

Meat&offal:zerodays

Milk:zerohours

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:

Dermatologicals,antiseptic,disinfectantofiodine-basedcompoundclass

ATCVetCode:

QD08AG03

5.1 Pharmacodynamicproperties

Free(molecular)iodineactivityisbasedonredoxmechanism(theoxidisingeffect

destroysmicro-organisms)andtheformingofsaltswithbacteriaprotein,the

Revised:May2011

AN:00478/2010

redoxreactioninvolvesvariouscellwallconstituents,whichareirreversibly

transformed.Itappearssulfhydryllinkages,inbacteriacellwallcomponents,are

specificallyaffectedbytheiodine.

KENOSTARThasbeendemonstratedefficientagainstbacteriacausingmastitis.

IthasbeentestedaccordingEuropeanNormsEN1656(fieldconditions)against

Staphylococcusaureus,Escherichiacoli,Streptococcusagalactiae,

Streptococcusdysgalactiae,StreptococcusuberisandCorynebacteriumbovis.

Thesestudieshavebeencarriedoutin2004atCIRLAMlaboratory.

5.2 Pharmacokineticproperties

Thepublishedliteratureindicatesthatiodinecoatedontotheskinrapidlyinteracts

withanyorganicmaterialpresentleavingverylittlefreeiodineforabsorption

throughtheepidermis.Ithasalsobeenreportedthatonlyasmallincreasein

serumiodineconcentrationisfoundafterteatdipping.

6. PHARMACEUTICALPARTICULARS

6.1 Listofexcipients

Glycerol

Sorbitol70%

SodiumBisulphite40%

EthoxylatedLanolin50%

SodiumIodate

SodiumChloride

SodiumHydroxide30%

SodiumIodide

XanthanGum

Alcohol(C13-C15)11MoleEthoxylate

Fattyacidamidepolyglycolether

CitricAcid

WaterPurified

6.2 Incompatibilities

Asageneralprecaution,it’sadvisablenottomixtheproductwithother

chemicals.Thisveterinarymedicinalproductmustnotbemixedwithother

veterinarymedicinalproducts.

6.3 Shelflife

Shelflifeoftheveterinaryproductaspackagedforsale:16months

Shelflifeafterfirstopeningtheimmediatepackaging:Tobeusedinthe6months

afterfirstopening.

6.4 Specialprecautionsforstorage

Storeuprightinthetightlyclosedoriginalcontainer

Protectfromfrost

Iftheproducthasfrozen,thawinawarmplaceandshakewellbeforeuse

Protectfromlight

Revised:May2011

AN:00478/2010

6.5 Natureandcompositionofimmediatepackaging

Adarkliquidcontainedin1,5,10,20,25,60litres,greyhigh-densitypolyethylene

drumswithHDPEcapsando-ringsealsand200litres,inbluehigh-density

polyethylenedrumswithHDPEcapsando-ringseals.

Notallpacksizesmaybemarketed.

6.6 Specialprecautionsforthedisposalofunusedveterinarymedicinalproduct

orwastematerialsderivedfromtheuseofsuchproducts,ifappropriate

Anyunusedveterinarymedicinalproductorwastematerialderivedfromsuch

veterinarymedicinalproductshouldbedisposedofinaccordancewithlocal

requirements.Theproductshouldnotenterwatercoursesasthisisdangerous

foraquaticorganisms.

7 MARKETINGAUTHORISATIONHOLDER

CIDLINESN.V.

Waterpoortstraat2

8900Ieper

Belgium

8. MARKETINGAUTHORISATIONNUMBER

Vm22136/4000

9. DATEOFFIRSTAUTHORISATION

19January2006

10. DATEOFREVISIONOFTHETEXT

May2011

7-8-2018

Seaweed consumption: remain vigilant to the risk of excess iodine intake

Seaweed consumption: remain vigilant to the risk of excess iodine intake

Over the last few years, seaweed has become increasingly common on our plates. Fresh, dried or as a food supplement, its iodine content varies and can sometimes be high. ANSES assessed the risk of excess iodine intake from the consumption of seaweed-based products. In view of the non-negligible risk of exceeding the upper limit of safe intake for iodine, the Agency advises against the consumption of seaweed and seaweed-based food supplements by certain at-risk populations, and recommends that regular con...

France - Agence Nationale du Médicament Vétérinaire

There are no news related to this product.